| 8:00 am - 5:00 pm |
Exhibition & Job Fair |
| 8:00 am - 8:40 am |
Continental Breakfast & Registration |
| 8:40 am - 8:50 am |
Welcome |
|
Xiangming Fang, President of SABPA SD, Sr. VP and CSO, eBioCenter Corporation |
| 8:50 am - 9:00 am |
Opening Address |
|
The Honorable Brian P. Bilbray, Member of Congress |
| 9:00 am - 10:00 am |
Session I. Frontier Research and Innovations |
|
Session Chair : Hui Cai, Chair of Board, SABPA, BOD of SDCA, President and CEO, Inflexion BioPartners |
|
Improving in vivo and Clinical Imaging with Activatable Cell-penetrating Peptides |
|
Roger Tsien, Professor, UCSD, 2008 Nobel Prize Laureate for Chemistry |
|
A Chemical Approach to Cell Fate Control |
|
Sheng Ding, Associate Professor, The Scripps Research Institute |
| 10:00 am - 10:30 am |
Coffee Break (Sponsored by Azopharma Product Development Group) |
| 10:30 am - 11:50 am |
Panel Discussion I. Evolving Business Models and Strategies
Description: The development of a business model and the implementation of the resulting strategy have become more complex over the years. Unless you are a major pharmaceutical company with large budgets and backup programs and compounds, implementation has required constant analysis and mid course corrections – and even radical changes. Several key factors have become variables that are constantly in flux.
- Regulatory authorities and changing attitudes
- Clinical results, both anticipated and actual
- Financial Markets and shifts in access to capital
- Partners and M&A – changing attitudes
- Global development and commercialization opportunities
Come listen to CEO’s, CBO’s, and CSO’s who are successfully managing these challenges in smaller start up companies through public companies and how the changing environment had impacted the evolution of their business model and strategic implementation.
|
|
Moderator : Jack Florio, Senior VP, Brinson Patrick Securities |
|
Stephen Chang, CSO, Stemgent |
|
David Kabakoff, Executive-in-Residence, Sofinnova Ventures |
|
Christopher LeMasters, CBO, Tragara Pharmaceuticals |
|
Randy Woods, President and CEO, Sequel Pharmaceuticals |
| 11:50 am - 1:15 pm |
Luncheon |
| 1:15 pm - 2:00 pm |
San Diego Bio-Pharma Achievement Award |
|
Moderator : Hui Li, Vice Chair of Board, SABPA, Senior Principal Scientist, Pfizer Global Research & Development |
|
Total Synthesis of Biologically Active Natural Products |
|
Award Recipient : Professor K.C. Nicolaou, The Scripps Research Institute & UCSD |
| 2:00 pm - 3:00 pm |
Session II. New Drug Development |
|
Session Chair : Cheng Jin, Executive Director, Business Development, PharmaLegacy Laboratories |
|
A Novel Approach to Drug Discovery and Development for Osteoporosis and Other Bone Diseases |
|
Hua Zhu (David) Ke, Scientific Executive Director, Bone and Mineral Metabolism, Amgen |
|
Oral Delivery of Oligonucleotides in Man [slide] |
|
Lloyd G. Tillman, Executive Director of Pharmaceutical Development, ISIS Pharmaceuticals |
| 3:10 pm - 3:30 pm |
Coffee Break (Sponsored by Azopharma Product Development Group) |
| 3:30 pm - 4:30 pm |
Panel Discussion II. Emerging Infectious Disease - What We Have Learnt from the "Swine Flu" Outbreak
Description: The recent swine flu outbreak is a reminder that infectious diseases represent an ongoing threat to public health. This distinguished panel of researchers, executives, and regulatory experts will offer insight into the lessons that can be learned by examining the swine flu outbreak as a case study. The audience will gain a new appreciation for the challenges presented in identifying and responding to the apparent spread of a disease. The panelists will discuss cutting-edge approaches for diagnosis, DNA vaccine and antiviral agents. Learn how the CDC and FDA have worked with private industry to ensure that public health needs are addressed in an expedited manner to combat the outbreak of disease. The panelists' insights will be illuminating for anyone with an interest in emerging infectious diseases. |
|
Moderator : Eldora Ellison, Director, Sterne, Kessler, Goldstein & Fox PLLC |
|
Graham Lidgard, Senior VP of R&D, Nanogen |
|
David Looney, Associate Professor, Medicine, UCSD Medical Center |
|
Ronald B. Moss, Executive VP, Clinical Development & Medical Affairs, NexBio |
|
Sean M. Sullivan, Executive Director, Pharmaceutical Sciences, Vical, Inc. |
|
Christina Yang, Senior VP, Clinical, Regulatory & Quality, Gen-Probe |
| 4:30 pm |
Closing |
| Feng Tian, President of SDCAA, BOD of SABPA |
| 4:30 pm - 5:00 pm |
Networking |
| |
| Final program as of June 5, 2009. All events will take place at Hilton San Diego/Del Mar , Del Mar.
|
|
